Drug intelligence / Profile preview

VGH-AD1

Development stage: Phase 2
Lead developer: Taipei Veterans General Hospital
Administration: Oral

Overview

VGH-AD1 is a scientific Chinese herbal medicine powder developed by Taipei Veterans General Hospital. It is being investigated as a treatment for Alzheimer's disease, specifically targeting nervous system diseases. The formulation is based on traditional Chinese medicine principles and is administered as a powder. Its precise mechanism of action and constituent herbs have not been disclosed in public sources, but it represents an approach rooted in traditional herbal therapy for neurodegenerative conditions such as Alzheimer's disease[1][2][5]. Clinical trials are ongoing to assess its efficacy and safety.

Brand names: VGH-AD1VGH-AD-1VGH-AD 1
Other names: VGH-AD1VGH-AD-1VGH-AD 1

Beyond the preview

Go deeper on VGH-AD1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGH-AD1.

Explore the full profile